Your browser is no longer supported. Please, upgrade your browser.
BriaCell Therapeutics Corp.
Index- P/E- EPS (ttm)- Insider Own18.90% Shs Outstand14.33M Perf Week4.11%
Market Cap112.65M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float5.01M Perf Month37.89%
Income- PEG- EPS next Q- Inst Own33.63% Short Float4.89% Perf Quarter43.43%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.12 Perf Half Y100.00%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year25.73%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.81 - 9.00 Perf YTD88.49%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-12.67% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low179.23% ATR0.60
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)67.39 Volatility8.30% 9.35%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.71 Prev Close7.56
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.09M Price7.86
Recom- SMA2018.12% SMA5035.51% SMA20071.18% Volume1,497,104 Change3.97%
Sep-16-21 09:00AM  
Sep-09-21 09:00AM  
Sep-01-21 09:15AM  
Aug-23-21 08:00AM  
Aug-19-21 08:00AM  
Aug-16-21 08:30AM  
Jul-14-21 07:22AM  
Jul-12-21 08:00AM  
Jul-08-21 11:20AM  
Jun-16-21 08:05AM  
Jun-10-21 08:05AM  
Jun-09-21 08:05AM  
Jun-07-21 07:50PM  
Jun-03-21 10:31AM  
Jun-02-21 07:12AM  
May-19-21 05:15PM  
May-11-21 06:30AM  
Apr-25-21 05:18AM  
Apr-21-21 08:00AM  
Apr-15-21 06:00PM  
Apr-12-21 01:45PM  
Mar-30-21 06:30AM  
Feb-26-21 02:24PM  
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.